Literature DB >> 23590591

pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.

John T Wilson1, Salka Keller, Matthew J Manganiello, Connie Cheng, Chen-Chang Lee, Chinonso Opara, Anthony Convertine, Patrick S Stayton.   

Abstract

Protein subunit vaccines offer important potential advantages over live vaccine vectors but generally elicit weaker and shorter-lived cellular immune responses. Here we investigate the use of pH-responsive, endosomolytic polymer nanoparticles that were originally developed for RNA delivery as vaccine delivery vehicles for enhancing cellular and humoral immune responses. Micellar nanoparticles were assembled from amphiphilic diblock copolymers composed of an ampholytic core-forming block and a redesigned polycationic corona block doped with thiol-reactive pyridyl disulfide groups to enable dual-delivery of antigens and immunostimulatory CpG oligodeoxynucleotide (CpG ODN) adjuvants. Polymers assembled into 23 nm particles with simultaneous packaging of CpG ODN and a thiolated protein antigen, ovalbumin (ova). Conjugation of ova to nanoparticles significantly enhanced antigen cross-presentation in vitro relative to free ova or an unconjugated, physical mixture of the parent compounds. Subcutaneous vaccination of mice with ova-nanoparticle conjugates elicited a significantly higher CD8(+) T cell response (0.5% IFN-γ(+) of CD8(+)) compared to mice vaccinated with free ova or a physical mixture of the two components. Significantly, immunization with ova-nanoparticle conjugates electrostatically complexed with CpG ODN (dual-delivery) enhanced CD8(+) T cell responses (3.4% IFN-γ(+) of CD8(+)) 7-, 18-, and 8-fold relative to immunization with conjugates, ova administered with free CpG, or a formulation containing free ova and CpG complexed to micelles, respectively. Similarly, dual-delivery carriers significantly increased CD4(+)IFN-γ(+) (Th1) responses and elicited a balanced IgG1/IgG2c antibody response. Intradermal administration further augmented cellular immune responses, with dual-delivery carriers inducing ∼7% antigen-specific CD8(+) T cells. This work demonstrates the ability of pH-responsive, endosomolytic nanoparticles to actively promote antigen cross-presentation and augment cellular and humoral immune responses via dual-delivery of protein antigens and CpG ODN. Hence, pH-responsive polymeric nanoparticles offer promise as a delivery platform for protein subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23590591      PMCID: PMC4042837          DOI: 10.1021/nn305466z

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  80 in total

1.  TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses.

Authors:  Eva Schlosser; Marc Mueller; Stefan Fischer; Sameh Basta; Dirk H Busch; Bruno Gander; Marcus Groettrup
Journal:  Vaccine       Date:  2008-02-06       Impact factor: 3.641

Review 2.  New horizons in adjuvants for vaccine development.

Authors:  Steven G Reed; Sylvie Bertholet; Rhea N Coler; Martin Friede
Journal:  Trends Immunol       Date:  2008-12-06       Impact factor: 16.687

Review 3.  Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.

Authors:  Yvonne Perrie; Afzal R Mohammed; Daniel J Kirby; Sarah E McNeil; Vincent W Bramwell
Journal:  Int J Pharm       Date:  2008-04-30       Impact factor: 5.875

Review 4.  Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.

Authors:  Jörg Vollmer; Arthur M Krieg
Journal:  Adv Drug Deliv Rev       Date:  2009-01-13       Impact factor: 15.470

Review 5.  Innovative strategies for co-delivering antigens and CpG oligonucleotides.

Authors:  Yogita Krishnamachari; Aliasger K Salem
Journal:  Adv Drug Deliv Rev       Date:  2009-01-19       Impact factor: 15.470

6.  In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy.

Authors:  Stefan Nierkens; Martijn H den Brok; Roger P M Sutmuller; Oliver M Grauer; Erik Bennink; Mary E Morgan; Carl G Figdor; Theo J M Ruers; Gosse J Adema
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

7.  Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy.

Authors:  Kyle E Broaders; Joel A Cohen; Tristan T Beaudette; Eric M Bachelder; Jean M J Fréchet
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

8.  Autophagy and toll-like receptors: a new link in cancer cells.

Authors:  Samuel Bertin; Valérie Pierrefite-Carle
Journal:  Autophagy       Date:  2008-11-06       Impact factor: 16.016

9.  Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation.

Authors:  Suzanne Flanary; Allan S Hoffman; Patrick S Stayton
Journal:  Bioconjug Chem       Date:  2009-02       Impact factor: 4.774

10.  Development of a novel endosomolytic diblock copolymer for siRNA delivery.

Authors:  Anthony J Convertine; Danielle S W Benoit; Craig L Duvall; Allan S Hoffman; Patrick S Stayton
Journal:  J Control Release       Date:  2008-10-17       Impact factor: 9.776

View more
  90 in total

Review 1.  Nanoparticle systems for cancer vaccine.

Authors:  Ru Wen; Afoma C Umeano; Yi Kou; Jian Xu; Ammad Ahmad Farooqi
Journal:  Nanomedicine (Lond)       Date:  2019-02-26       Impact factor: 5.307

2.  Engineered Materials for Cancer Immunotherapy.

Authors:  Alexander S Cheung; David J Mooney
Journal:  Nano Today       Date:  2015-08-01       Impact factor: 20.722

3.  Three-dimensional localization of polymer nanoparticles in cells using ToF-SIMS.

Authors:  Daniel J Graham; John T Wilson; James J Lai; Patrick S Stayton; David G Castner
Journal:  Biointerphases       Date:  2015-06-03       Impact factor: 2.456

Review 4.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

5.  Temperature-activated nucleic acid nanostructures.

Authors:  Ke Zhang; Xiao Zhu; Fei Jia; Evelyn Auyeung; Chad A Mirkin
Journal:  J Am Chem Soc       Date:  2013-09-16       Impact factor: 15.419

6.  Intracellular delivery system for antibody-Peptide drug conjugates.

Authors:  Geoffrey Y Berguig; Anthony J Convertine; Shani Frayo; Hanna B Kern; Erik Procko; Debashish Roy; Selvi Srinivasan; Daciana H Margineantu; Garrett Booth; Maria Corinna Palanca-Wessels; David Baker; David Hockenbery; Oliver W Press; Patrick S Stayton
Journal:  Mol Ther       Date:  2015-02-11       Impact factor: 11.454

Review 7.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

8.  Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells.

Authors:  Frances C Knight; Pavlo Gilchuk; Amrendra Kumar; Kyle W Becker; Sema Sevimli; Max E Jacobson; Naveenchandra Suryadevara; Lihong Wang-Bishop; Kelli L Boyd; James E Crowe; Sebastian Joyce; John T Wilson
Journal:  ACS Nano       Date:  2019-10-04       Impact factor: 15.881

Review 9.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

10.  Nanoparticle Design Strategies for Effective Cancer Immunotherapy.

Authors:  Praveena Velpurisiva; Aniket Gad; Brandon Piel; Rahul Jadia; Prakash Rai
Journal:  J Biomed (Syd)       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.